HER-2 low in breast cancer: A new perspective for anti-HER-2 therapy
Crossref DOI link: https://doi.org/10.30574/msarr.2025.13.1.0232
Published Online: 2025-01-30
Update policy: https://doi.org/10.30574/msarr.ourcrossmarkpolicy
Afifah Jilan Hasninda,
Willy Sandhika,
